US › Healthcare

Galectin Therapeutics Inc (GALT)

US · Healthcare · Biotechnology

$3.62-2.43%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-9.1M

EPS

$-0.14

EPS estimate

$-0.09

EPS came in at -0.14 against a street estimate of -0.09 — a miss of 55.6%.

Key statistics

Market cap

$365.1M

Forward P/E

4.5

P/B

207.70

Book value

$-2.10

EPS (TTM)

$-0.43

52-week high

$7.13

52-week low

$2.03

50-day MA

$3.82

200-day MA

$3.21

Beta

0.38

Analyst view

Analysts rate Galectin Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.00.

Shareholding

Insiders

53.08%

Institutions

15.66%

Largest institutional holders

Fund	Stake
BlackRock Inc	2.96%
Vanguard Capital Management, LLC	2.15%
Geode Capital Management, LLC	1.30%
Advisor Group Holdings, Inc.	1.19%
Marshall Wace Asset Management Ltd	0.82%
Sontag Advisory LLC	0.72%
State Street Corp	0.56%
Commonwealth Equity Services, LLC	0.40%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Galectin Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.